|
Market Closed -
Nasdaq
21:00:00 22/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 28.97 USD | -1.36% |
|
+0.14% | +6.66% |
| 09-22 | Top Midday Decliners | MT |
| 09-22 | Celldex Therapeutics, Inc. - Special Call |
Company Valuation: Celldex Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,803 | 2,099 | 2,169 | 1,677 | 1,805 | 2,306 | - | - |
| Change | - | 16.42% | 3.32% | -22.7% | 7.65% | 27.8% | - | - |
| Enterprise Value (EV) 1 | 1,395 | 1,794 | 1,745 | 951.2 | 1,286 | 1,644 | 1,668 | 1,713 |
| Change | - | 28.64% | -2.73% | -45.5% | 35.21% | 27.83% | 1.44% | 2.72% |
| P/E | -23.6x | -18.6x | -13.6x | -10.3x | -6.96x | -7x | -6.86x | -8.58x |
| PBR | - | - | - | 2.25x | 3.43x | 3.89x | 3.85x | 4.38x |
| PEG | - | -0.4x | -0.6x | 0.6x | -0.1x | -0.92x | -3.43x | 0.4x |
| Capitalization / Revenue | 388x | 891x | 315x | 239x | 1,168x | 1,247x | 263x | 18.8x |
| EV / Revenue | 300x | 761x | 254x | 136x | 832x | 889x | 190x | 14x |
| EV / EBITDA | - | - | -11.3x | -4.96x | -4.53x | -5.07x | -4.77x | -6.92x |
| EV / EBIT | -19.6x | -15.6x | -12.3x | -4.88x | -4.48x | -4.87x | -4.49x | -5.52x |
| EV / FCF | -22.4x | -17x | -16x | -5.96x | -6.02x | -5.98x | -6.02x | -11.2x |
| FCF Yield | -4.46% | -5.88% | -6.25% | -16.8% | -16.6% | -16.7% | -16.6% | -8.9% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.64 | -2.4 | -2.92 | -2.45 | -3.9 | -4.196 | -4.28 | -3.423 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 4.651 | 2.357 | 6.883 | 7.02 | 1.545 | 1.85 | 8.76 | 122.6 |
| EBITDA 1 | - | - | -154.5 | -191.9 | -284 | -324.3 | -349.5 | -247.7 |
| EBIT 1 | -71.24 | -115.2 | -142 | -195.1 | -287.4 | -337.6 | -371.7 | -310.1 |
| Net income 1 | -70.51 | -112.3 | -141.4 | -157.9 | -258.8 | -319.2 | -360.9 | -315.9 |
| Net Debt 1 | -408.2 | -305 | -423.6 | -725.3 | -518.6 | -662.3 | -638.7 | -593.3 |
| Reference price 2 | 38.64 | 44.57 | 39.66 | 25.27 | 27.16 | 29.37 | 29.37 | 29.37 |
| Nbr of stocks (in thousands) | 46,664 | 47,100 | 54,689 | 66,344 | 66,449 | 78,530 | - | - |
| Announcement Date | 28/02/22 | 28/02/23 | 26/02/24 | 27/02/25 | 25/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7x | 888.74x | -5.07x | -.--% | 2.31B | |
| 19.17x | 6.81x | 13.53x | 1.55% | 66.22B | |
| 30.52x | 8.19x | 25.9x | 0.05% | 55.2B | |
| 36.31x | 6.45x | 19.27x | 0.89% | 52.79B | |
| 35.25x | 3.42x | 14.76x | -.--% | 45.53B | |
| 50.87x | 5.89x | 32.33x | -.--% | 43.94B | |
| -20.15x | 197.1x | -21.43x | -.--% | 41.64B | |
| 29.51x | 8.36x | 21.63x | 0.36% | 34B | |
| 29.85x | 6.32x | 16.4x | -.--% | 25.84B | |
| 32.16x | 5.92x | 19.93x | -.--% | 23.51B | |
| Average | 23.65x | 113.72x | 13.72x | 0.28% | 39.1B | |
| Weighted average by Cap. | 26.57x | 31.98x | 15.75x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CLDX Stock
- Valuation Celldex Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
